Emerging strategies for the treatment of older patients with acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q38818726

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Emerging strategies for the treatment of older patients with acute myeloid leukemia.

@en

type

Item

label

Emerging strategies for the treatment of older patients with acute myeloid leukemia.

@en

prefLabel

Emerging strategies for the treatment of older patients with acute myeloid leukemia.

@en

P1476

Emerging strategies for the treatment of older patients with acute myeloid leukemia

@en

P2093

Gloria Iacoboni

http://www.w3.org/2001/XMLSchema#string

Pau Montesinos

http://www.w3.org/2001/XMLSchema#string

P2860

Progress in acute myeloid leukemia

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

The Ras superfamily at a glance

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

P304

1583-1593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-016-2666-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Adriano Venditti

Miguel A Sanz

P577

2016-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27118541

http://www.w3.org/2001/XMLSchema#string